-
Document de presse | 2020.08.12
The behaviour of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells. However, in the more than 20 years since their use began, the molecular mechanisms that underlie this therapy are still little understood. For the first time, scientists from the CNRS, Institut Pasteur and Université...
-
Article | 2020.08.20
Industrial property
The Institut Pasteur is in the world's top 10 list for US and European patents granted in the field of life sciences for the period 2010-2014.
-
Article | 2020.08.20
Licensing opportunities
Available TechnologiesIf you are interested in currently available technologies from the Institut Pasteur in 4 main categories (Diagnostic, Therapeutics, Vaccines and Technology), please contact the Business Development teamContact us
-
Article | 2020.08.20
R&D collaborations
The combination of our scientific expertise and industrial awareness will enable you to identify innovative solutions to meet your challenges.
-
Article | 2020.08.20
Other contracts
By partnering with the Institut Pasteur, you benefit from access to science, knowledge, skills and cutting-edge infrastructures.
-
Article | 2020.08.20
Post-contract Management
In order to address the challenges of product development costs associated with the high failure rate of development collaborations, the Industrial Agreements Office builds trustworthy, long-term relationships with industrial partners in full transparency.
-
Article | 2020.08.20
The Carnot Label
Founded in 2006, the Carnot Label, granted by the French government, was designed to develop partnership-based research, meaning research conducted by public laboratories in partnership with socio-economic players, primarily industry (from SMEs to large corporations), to serve their needs.
-
Document de presse | 2020.04.24
Development and evaluation of four serological assays to detect SARS-CoV-2 antibodies and two assays to detect neutralizing antibodies
Approximately four months after the initial description of cases of atypical pneumonia in Wuhan, China, in December 2019, COVID-19 had become a major pandemic threat. By April 12, 2020, around half of the world's population was in lockdown, with 1.8 million officially diagnosed cases. Scientists from the Institut Pasteur, the CNRS, Inserm and Université de Paris conducted a pilot study to...
-
Article | 2020.08.20
Innovation Our Organization Biographies
Dr. Larzul, PhD, has joined the department of Technology Transfer & Industrial Partnerships in 2018 has head of the Detection, Financing of Innovation & Entrepreneurship Office.Daniel Larzul gained his first industry experience when he joined the pharmaceutical company Ipsen, then contributed to the creation of the molecular diagnostics startup BioInnova. He subsequently joined Texcell,...
-
Page avancée | 2020.08.26
About us
The Technology Transfer and Industrial Partnership Department helps researchers and industrial partners, from initial scientific discovery through exploitation and implementation of inventions.
